Print

Amarin Corporation PLC (AMRN) Announces Publication of ANCHOR Phase 3 Clinical Trial Results in The American Journal of Cardiology  
7/24/2012 9:22:10 AM

BEDMINSTER, N.J., and DUBLIN, Ireland, July 24, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, announced today that the results of its pivotal ANCHOR Phase 3 clinical trial are now available electronically through The American Journal of Cardiology and are scheduled for print publication in the October 2012 issue.
//-->